{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:29:21Z","timestamp":1793212161745,"version":"4.5.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T00:00:00Z","timestamp":1731024000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics and Research in Hepatology and Gastroenterology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.clinre.2024.102483","type":"journal-article","created":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T23:14:33Z","timestamp":1729638873000},"page":"102483","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real-world effectiveness and safety of CT-P13, an infliximab biosimilar, for inflammatory bowel diseases: A prospective national observational cohort study (ReFLECT study)"],"prefix":"10.1016","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4753-6676","authenticated-orcid":false,"given":"David","family":"Laharie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoram","family":"Bouhnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucine","family":"Vuitton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Am\u00e9lie","family":"Biron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaelle","family":"Pierron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Brault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryse","family":"Assing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amira","family":"Bouzidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lien","family":"Amiot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"Nancey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.clinre.2024.102483_bib0001","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1093\/ecco-jcc\/jjw090","article-title":"Changes in biosimilar knowledge among european crohn's colitis organization [ECCO] members: an updated survey","volume":"10","author":"Danese","year":"2016","journal-title":"J Crohns Colitis"},{"issue":"10","key":"10.1016\/j.clinre.2024.102483_bib0002","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1177\/2050640619883704","article-title":"Changes in inflammatory bowel disease patients' perspectives on biosimilars: a follow-up survey","volume":"7","author":"Peyrin-Biroulet","year":"2019","journal-title":"United Euro Gastroenterol J"},{"key":"10.1016\/j.clinre.2024.102483_bib0003","unstructured":"European Medicines Agency. Remicade (infliximab) European public assessment report product information. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/remicade. Published 1999. Updated 26 April 2022. Accessed 22 September 2022."},{"key":"10.1016\/j.clinre.2024.102483_bib0004","unstructured":"European Medicines Agency. Inflectra (Infliximab) European public assessment report product information. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/inflectra. Published 2013. Updated 12 May 2022. Accessed 22 September 2022."},{"key":"10.1016\/j.clinre.2024.102483_bib0005","unstructured":"Celltrion Healthcare. Remsima\u00ae. https:\/\/www.celltrionhealthcare.com\/en-us\/products\/product\/?pkey=5. Published 2020. Accessed 22 September 2022."},{"key":"10.1016\/j.clinre.2024.102483_bib0006","unstructured":"GaBi Online (Generics and Biosimilars Initaitive). Biosimilars of infliximab. https:\/\/www.gabionline.net\/biosimilars\/general\/Biosimilars-of-infliximab. Published 2015. Updated 27 November 2020. Accessed 22 September 2022."},{"key":"10.1016\/j.clinre.2024.102483_bib0007","series-title":"Remicade biosimilars hit european market","year":"2015"},{"key":"10.1016\/j.clinre.2024.102483_bib0008","unstructured":"European Medicines Agency. Remsima (Infliximab) European public assessment report product information. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/remsima. Published 2013. Updated 17 May 2022. Accessed 21 November 2024."},{"key":"10.1016\/j.clinre.2024.102483_bib0009","doi-asserted-by":"crossref","unstructured":"Park W, Hrycaj P, Jeka S, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis. 2013;72(10):1605-12. https:\/\/doi.org\/10.1136\/annrheumdis-2012-203091.","DOI":"10.1136\/annrheumdis-2012-203091"},{"key":"10.1016\/j.clinre.2024.102483_bib0010","doi-asserted-by":"crossref","unstructured":"Yoo DH, Hrycaj P, Miranda P, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis. 2013;72(10):1613-20. https:\/\/doi.org\/10.1136\/annrheumdis-2012-203090.","DOI":"10.1136\/annrheumdis-2012-203090"},{"key":"10.1016\/j.clinre.2024.102483_bib0011","doi-asserted-by":"crossref","unstructured":"Meyer A, Rudant J, Drouin J, Coste J, Carbonnel F, Weill A. The effectiveness and safety of infliximab compared with biosimilar CT-P13, in 3112 patients with ulcerative colitis. Aliment Pharmacol Ther. 2019;50(3):269-77. https:\/\/doi.org\/10.1111\/apt.15323.","DOI":"10.1111\/apt.15323"},{"key":"10.1016\/j.clinre.2024.102483_bib0012","doi-asserted-by":"crossref","unstructured":"Meyer A, Rudant J, Drouin J, Weill A, Carbonnel F, Coste J. Effectiveness and Safety of Reference Infliximab and Biosimilar in Crohn Disease: A French Equivalence Study. Ann Intern Med. 2019;170(2):99-107. https:\/\/doi.org\/10.7326\/M18-1512.","DOI":"10.7326\/M18-1512"},{"issue":"6","key":"10.1016\/j.clinre.2024.102483_bib0013","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/joim.12880","article-title":"Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trial","volume":"285","author":"Goll","year":"2019","journal-title":"J Intern Med"},{"issue":"5","key":"10.1016\/j.clinre.2024.102483_bib0014","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s40259-020-00438-7","article-title":"Efficacy and safety of CT-P13 in inflammatory bowel disease after switching from originator infliximab: exploratory analyses from the NOR-SWITCH main and extension trials","volume":"34","author":"Jorgensen","year":"2020","journal-title":"BioDrugs"},{"issue":"10086","key":"10.1016\/j.clinre.2024.102483_bib0015","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1016\/S0140-6736(17)30068-5","article-title":"Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial","volume":"389","author":"Jorgensen","year":"2017","journal-title":"Lancet"},{"issue":"Supplement_1","key":"10.1016\/j.clinre.2024.102483_bib0016","doi-asserted-by":"crossref","first-page":"i161-i2","DOI":"10.1093\/ecco-jcc\/jjac190.0126","article-title":"DOP86 subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn's disease: a phase 3, randomised, placebo-controlled study (LIBERTY-CD)","volume":"17","author":"Colombel","year":"2023","journal-title":"J Crohn's Colitis"},{"issue":"Supplement_1","key":"10.1016\/j.clinre.2024.102483_bib0017","doi-asserted-by":"crossref","first-page":"i623-i4","DOI":"10.1093\/ecco-jcc\/jjac190.0622","article-title":"P492 subcutaneous infliximab (CT-P13 SC) as maintenance therapy for ulcerative colitis: a phase 3, randomized, placebo-controlled study: results of the LIBERTY-UC study","volume":"17","author":"Sands","year":"2023","journal-title":"J Crohn's Colitis"},{"key":"10.1016\/j.clinre.2024.102483_bib0018","unstructured":"ClinicalTrials.gov. National observational study on the use of inflectra\u2122 an infliximab biosimilar in real life (ReFLECT). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02925338. Published 2016. Updated 7 February 2022. Accessed 22 September 2022."},{"issue":"9","key":"10.1016\/j.clinre.2024.102483_bib0019","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1111\/jgh.14645","article-title":"Long-term efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: a retrospective multicenter study","volume":"34","author":"Kim","year":"2019","journal-title":"J Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.clinre.2024.102483_bib0020","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1136\/ejhpharm-2020-002410","article-title":"Long-term effectiveness and pharmacokinetics of the infliximab biosimilar CT-P13 after switching from the originator during the treatment of inflammatory bowel disease","volume":"29","author":"Martin-Gutierrez","year":"2022","journal-title":"Eur J Hosp Pharm"},{"issue":"1","key":"10.1016\/j.clinre.2024.102483_bib0021","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1093\/ibd\/izy227","article-title":"Drug survival and immunogenicity after switching from remicade to biosimilar CT-P13 in inflammatory bowel disease patients: two-year follow-up of a prospective observational cohort study","volume":"25","author":"Smits","year":"2019","journal-title":"Inflamm Bowel Dis"},{"issue":"5","key":"10.1016\/j.clinre.2024.102483_bib0022","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1007\/s12325-022-02104-6","article-title":"Impact of infliximab-dyyb (infliximab biosimilar) on clinical and patient-reported outcomes: 1-year follow-up results from an observational real-world study among patients with inflammatory bowel disease in the US and Canada (the ONWARD study)","volume":"39","author":"Abraham","year":"2022","journal-title":"Adv Ther"},{"issue":"8","key":"10.1016\/j.clinre.2024.102483_bib0023","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1080\/14712598.2023.2200883","article-title":"Real-world observational cohort study of treatment patterns and safety outcomes of infliximab biosimilar CT-P13 for the treatment of inflammatory bowel disease (CONNECT-IBD)","volume":"23","author":"Bokemeyer","year":"2023","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"10.1016\/j.clinre.2024.102483_bib0024","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1517\/14740338.2016.1112375","article-title":"Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety?","volume":"15","author":"Murdaca","year":"2016","journal-title":"Expert Opin Drug Saf"}],"container-title":["Clinics and Research in Hepatology and Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740124002043?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740124002043?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T01:48:02Z","timestamp":1733363282000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2210740124002043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":24,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S2210740124002043"],"URL":"https:\/\/doi.org\/10.1016\/j.clinre.2024.102483","relation":{},"ISSN":["2210-7401"],"issn-type":[{"value":"2210-7401","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world effectiveness and safety of CT-P13, an infliximab biosimilar, for inflammatory bowel diseases: A prospective national observational cohort study (ReFLECT study)","name":"articletitle","label":"Article Title"},{"value":"Clinics and Research in Hepatology and Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinre.2024.102483","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"102483"}}